• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

    5.445 -0.075 (-1.36%)
    Streaming Delayed Price Updated: 3:32 PM EDT, Oct 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 96,966
    Open 5.410
    Bid (Size) 5.430 (2)
    Ask (Size) 5.470 (5)
    Prev. Close 5.520
    Today's Range 5.410 - 5.560
    52wk Range 3.810 - 9.813
    Shares Outstanding 113,793,338
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
    From Precision BioSciences, Inc.
    Via Business Wire

    Performance

    YTD
    +16.1%
    +16.1%
    1 Month
    +8.9%
    +8.9%
    3 Month
    +31.8%
    +31.8%
    6 Month
    +21.3%
    +21.3%
    1 Year
    -39.2%
    -39.2%

    More News

    Read More
    Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
    From Precision BioSciences, Inc.
    Via Business Wire
    Earnings Scheduled For August 7, 2025
    Via Benzinga
    DTIL Revenue Drops 99%
    Via The Motley Fool
    Topics Intellectual Property
    Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’
    Via Stocktwits
    Discover the top movers in Wednesday's pre-market session.
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
    From Precision BioSciences, Inc.
    Via Business Wire
    Sidoti Events, LLC's Virtual May Micro-Cap Conference
    Via ACCESS Newswire
    Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
    From Precision BioSciences, Inc.
    Via Business Wire
    Earnings Scheduled For May 15, 2025
    Via Benzinga
    Uncovering Potential: Precision BioSciences's Earnings Preview
    Via Benzinga
    Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Precision BioSciences, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
    From Precision BioSciences, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Precision BioSciences, Inc. - Common Stock publicly traded?
    Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.
    What exchange does Precision BioSciences, Inc. - Common Stock trade on?
    Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?
    The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market
    What is the current price of Precision BioSciences, Inc. - Common Stock?
    The current price of Precision BioSciences, Inc. - Common Stock is 5.445
    When was Precision BioSciences, Inc. - Common Stock last traded?
    The last trade of Precision BioSciences, Inc. - Common Stock was at 10/01/25 03:32 PM ET
    What is the market capitalization of Precision BioSciences, Inc. - Common Stock?
    The market capitalization of Precision BioSciences, Inc. - Common Stock is 619.60M
    How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?
    Precision BioSciences, Inc. - Common Stock has 620M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.